DermTech's Q4 earnings report showed a match with the estimated EPS, indicating stability in their financial performance. The consistent revenue growth compared to the previous year is positive, but since the EPS met expectations without exceeding them, the short-term impact on the stock price is likely to be neutral. Historical data shows a positive stock price movement following an earnings beat last quarter, but this neutral result may not generate the same response.